Top

Published in:

01-05-2021 | Alzheimer's Disease | Original Article

Positive association of a Sirt1 variant and parameters of oxidative stress on Alzheimer’s disease

Authors: Daniela Camporez, Luciano Belcavello, Jucimara Ferreira Figueiredo Almeida, Geralda Gillian Silva-Sena, Lúcia Helena Sagrillo Pimassoni, Renato Lírio Morelato, Maria do Carmo Pimentel Batitucci, Flavia de Paula

Published in: Neurological Sciences | Issue 5/2021

Abstract

Alzheimer’s disease (AD) is a complex neurodegenerative disorder and the most common type of dementia in the elderly. Although its cause is not completely known, several studies suggest that oxidative stress plays an important role in the etiology of this disease. The SIRT1 and SOD2 proteins are linked to pathways that may impair oxidative stress. In this study, we analyzed the association between polymorphisms in these genes and in the APOE gene, through RT-PCR, as well as between environmental factors and the risk of AD. Additionally, the thiobarbituric acid reactive substance assay was performed to estimate the plasma level of malondialdehyde (MDA), a biomarker of lipid peroxidation. Furthermore, some cytogenetic studies indicate that cells of AD patients show increased chromosomal damage; thus, we performed the micronucleus cytome assay to assess cytogenetic damage in AD patients. As expected, the APOE polymorphisms were found to be highly associated with AD. Additionally, the CT genotype of the SIRT1 gene showed a positive association with the disease. The frequencies of genomic damage (micronucleus, buds, nucleoplasmic bridges and binucleated cells), the presence of cell death biomarkers (condensed chromatin, karyorrhexis and pyknosis), and the plasma level of MDA were significantly greater in AD patients than in controls. Our results support the hypothesis that AD is a condition with increased oxidative stress and genomic instability, which may contribute to the neurodegeneration in AD.

Prince M, Comas-Herrera A, Knapp M et al (2016) World Alzheimer Report 2016 Improving healthcare for people living with dementia. Coverage, Quality and costs now and in the future. In: Alzheimer’s Disease International (ADI). Alzheimer’s Disease International (ADI), London, pp 1–140

Pimplikar SW, Nixon RA, Robakis NK et al (2010) Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J Neurosci 30:14946–14954. https://doi.org/10.1523/JNEUROSCI.4305-10.2010CrossRefPubMedPubMedCentral

Karch CM, Goate AM (2014) Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 1–9. https://doi.org/10.1016/j.biopsych.2014.05.006

Hardas SS, Sultana R, Clark AM et al (2013) Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol 1:80–85CrossRef

Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345:91–104CrossRef

Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 45:1594–1601CrossRef

Lovell MA, Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer’s disease. J Neurosci Res 85:3036–3040CrossRef

Benedetti D, Nunes E, Sarmento M et al (2013) Genetic damage in soybean workers exposed to pesticides: evaluation with the comet and buccal micronucleus cytome assays. Mutat Res Genet Toxicol Environ Mutagen 752:28–33CrossRef

Celik A, Diler SB, Eke D (2010) Assessment of genetic damage in buccal epithelium cells of painters: micronucleus, nuclear changes, and repair index. DNA Cell Biol 29:277–284CrossRef

10.

Holland N, Bolognesi C, Kirsch-Volders M et al (2008) The micronucleus assay in human buccal cells as a tool for biomonitoring DNA damage: the HUMN project perspective on current status and knowledge gaps. Mutat Res Rev Mutat Res 659:93–108CrossRef

11.

Migliore L, Coppedè F, Fenech M, Thomas P (2011) Association of micronucleus frequency with neurodegenerative diseases. Mutagenesis 26:85–92CrossRef

12.

Ortiz GG, Moisés FPP, Mireles-Ramírez M et al (2017) Chapter One-Oxidative stress: love and hate history in central nervous system. Adv Protein Chem Struct Biol 108:1–31CrossRef

13.

Rizzi L, Roriz-Cruz M (2018) Sirtuin 1 and Alzheimer’s disease: an up-to-date review. Neuropeptides 71:54–60. https://doi.org/10.1016/j.npep.2018.07.001CrossRef

14.

Lee HJ, Yang SJ (2017) Aging-related correlation between serum sirtuin 1 activities and basal metabolic rate in women, but not in men. Clin Nutr Res 6:18–26CrossRef

15.

Wiener HW, Perry RT, Chen Z et al (2007) A polymorphism in SOD2 is associated with development of Alzheimer’s disease. Genes Brain Behav 6:770–776. https://doi.org/10.1111/j.1601-183X.2007.00308.xCrossRefPubMed

16.

Zhao N, Liu C-C, Qiao W, Bu G (2018) Apolipoprotein E, receptors, and modulation of Alzheimer’s disease. Biol Psychiatry 83:347–357. https://doi.org/10.1016/j.biopsych.2017.03.003CrossRefPubMed

17.

Islam MT (2017) Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res 39:73–82. https://doi.org/10.1080/01616412.2016.1251711CrossRefPubMed

18.

Marnett LJ (1999) Lipid peroxidation—DNA damage by malondialdehyde. Mutat Res Fundam Mol Mech Mutagen 424:83–95CrossRef

19.

Pizzimenti S, Ciamporcero ES, Daga M et al (2013) Interaction of aldehydes derived from lipid peroxidation and membrane proteins. Front Physiol 4:242CrossRef

20.

Uchida K (2013) Redox-derived damage-associated molecular patterns: ligand function of lipid peroxidation adducts. Redox Biol 1:94–96CrossRef

21.

Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43:2412–2412. https://doi.org/10.1212/WNL.43.11.2412-aCrossRefPubMed

22.

McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269CrossRef

23.

McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–939. https://doi.org/10.1212/WNL.34.7.939CrossRefPubMed

24.

Fagundes Chaves ML, Camozzato AL, Godinho C et al (2007) Validity of the clinical dementia rating scale for the detection and staging of dementia in Brazilian patients. Alzheimer Dis Assoc Disord 21:210–217. https://doi.org/10.1097/WAD.0b013e31811ff2b4CrossRef

25.

Macedo Montaño MBM, Ramos LR (2005) Validade da versão em português da Clinical Dementia Rating. Rev Saude Publica 39:912–917. https://doi.org/10.1590/S0034-89102005000600007CrossRef

26.

Arevalo-Rodriguez I, Smailagic N, Roquéi Figuls M et al (2015) Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev

27.

Menegardo CS, Friggi FA, Scardini JB et al (2019) Sundown syndrome in patients with Alzheimer’s disease dementia. Dement Neuropsychol 13:469–474. https://doi.org/10.1590/1980-57642018dn13-040015CrossRefPubMedPubMedCentral

28.

Carrano AV, Natarajan AT (1988) Considerations for population monitoring using cytogenetic techniques. Mutat Res Genet Toxicol 204:379–406CrossRef

29.

Fenech M, Morley A (1985) Solutions to the kinetic problem in the micronucleus assay. Cytobios 43:233–246PubMed

30.

Bolognesi C, Fenech M (2013) Micronucleus assay in human cells: lymphocytes and buccal cells. In: Genotoxicity Assessment. Springer, pp 191–207

31.

Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52:302–310. https://doi.org/10.1016/S0076-6879(78)52032-6CrossRefPubMed

32.

Valenzuela A (1991) The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress. Life Sci 48:301–309CrossRef

33.

Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71:621 s–629 sCrossRef

34.

Coskun PE, Beal MF, Wallace DC (2004) Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A 101:10726–10731CrossRef

35.

Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 36:747–751CrossRef

36.

Pei L, Wallace DC (2018) Mitochondrial Etiology of Neuropsychiatric Disorders. Biol Psychiatry 83:722–730CrossRef

37.

Treviño-Saldaña N, García-Rivas G (2017) Regulation of sirtuin-mediated protein deacetylation by cardioprotective phytochemicals. Oxidative Med Cell Longev 2017:1–16. https://doi.org/10.1155/2017/1750306CrossRef

38.

Hadar A, Milanesi E, Walczak M et al (2018) SIRT1, miR-132 and miR-212 link human longevity to Alzheimer’s disease. Sci Rep 8:8465. https://doi.org/10.1038/s41598-018-26547-6CrossRefPubMedPubMedCentral

39.

Pasinetti GM, Zhao Z, Qin W et al (2007) Caloric intake and Alzheimer’s disease. In: Mechanisms of dietary restriction in aging and disease. Karger Publishers, pp 159–175

40.

Julien C, Tremblay C, Émond V et al (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68:48–58CrossRef

41.

Muñoz SS, Garner B, Ooi L (2019) Understanding the role of ApoE fragments in Alzheimer’s disease. Neurochem Res 44:1297–1305. https://doi.org/10.1007/s11064-018-2629-1CrossRefPubMed

42.

Uddin MS, Kabir MT, Al Mamun A et al (2019) APOE and Alzheimer’s disease: evidence mounts that targeting APOE4 may combat Alzheimer’s pathogenesis. Mol Neurobiol 56:2450–2465. https://doi.org/10.1007/s12035-018-1237-zCrossRefPubMed

43.

Corder E, Saunders A, Strittmatter W et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923. https://doi.org/10.1126/science.8346443CrossRefPubMed

44.

Farrer LA, Cupples LA, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. Jama 278:1349–1356CrossRef

45.

Ewbank DC (2004) The APOE gene and differences in life expectancy in Europe. J Gerontol Ser A Biol Med Sci 59:B16–B20CrossRef

46.

Ji Y, Liu M, Huo YR et al (2013) Apolipoprotein Ε ε4 frequency is increased among Chinese patients with frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord 36:163–170CrossRef

47.

Bosco P, Guéant-Rodríguez RM, Anello G et al (2005) Allele ε4 of APOE is a stronger predictor of Alzheimer risk in Sicily than in continental South Italy. Neurosci Lett 388:168–172. https://doi.org/10.1016/j.neulet.2005.06.056CrossRefPubMed

48.

Miyata M, Smith JD (1996) Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides. Nat Genet 14:55–61CrossRef

49.

Rebeck GW, Kindy M, LaDu MJ (2002) Apolipoprotein E and Alzheimer’s disease: the protective effects of ApoE2 and E3. J Alzheimers Dis 4:145–154CrossRef

50.

Nielsen HM, Chen K, Lee W et al (2017) Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimers Res Ther 9:5. https://doi.org/10.1186/s13195-016-0231-9CrossRefPubMedPubMedCentral

51.

Nozik-Grayck E, Suliman HB, Piantadosi CA (2005) Extracellular superoxide dismutase. Int J Biochem Cell Biol 37:2466–2471CrossRef

52.

Migliore L, Testa A, Scarpato R et al (1997) Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with Alzheimer’s disease. Hum Genet 101:299–305CrossRef

53.

Petrozzi L, Lucetti C, Scarpato R et al (2002) Cytogenetic alterations in lymphocytes of Alzheimer’s disease and Parkinson’s disease patients. Neurol Sci 23:s97–s98CrossRef

54.

Fenech M, Holland N, Zeiger E et al (2011) The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells—past, present and future. Mutagenesis 26:239–245CrossRef

55.

Lee SL, Thomas P, Hecker J et al (2015) Chromosomal DNA damage measured using the cytokinesis-block micronucleus cytome assay is significantly associated with cognitive impairment in South Australians. Environ Mol Mutagen 56:32–40. https://doi.org/10.1002/em.21890CrossRefPubMed

56.

Sánchez-Flores M, Marcos-Pérez D, Lorenzo-López L et al (2018) Frailty syndrome and genomic instability in older adults: suitability of the cytome micronucleus assay as a diagnostic tool. J Gerontol Ser A 73:864–872. https://doi.org/10.1093/gerona/glx258CrossRef

57.

Thomas P, Fenech M (2007) A review of genome mutation and Alzheimer’s disease. Mutagenesis 22:15–33. https://doi.org/10.1093/mutage/gel055CrossRefPubMed

58.

Migliore L, Fontana I, Trippi F et al (2005) Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26:567–573. https://doi.org/10.1016/j.neurobiolaging.2004.07.016CrossRefPubMed

59.

Nielsen F, Mikkelsen BB, Nielsen JB et al (1997) Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 43:1209–1214CrossRef

60.

Bourdel-Marchasson I, Delmas-Beauviex MC, Peuchant E et al (2001) Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 30:235–241. https://doi.org/10.1093/ageing/30.3.235CrossRefPubMed

61.

Torres LL, Quaglio NB, De Souza GT et al (2011) Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. https://doi.org/10.3233/JAD-2011-110284

Title: Positive association of a Sirt1 variant and parameters of oxidative stress on Alzheimer’s disease
Authors: Daniela Camporez
Luciano Belcavello
Jucimara Ferreira Figueiredo Almeida
Geralda Gillian Silva-Sena
Lúcia Helena Sagrillo Pimassoni
Renato Lírio Morelato
Maria do Carmo Pimentel Batitucci
Flavia de Paula
Publication date: 01-05-2021
Publisher: Springer International Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Published in: Neurological Sciences / Issue 5/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04704-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Positive association of a Sirt1 variant and parameters of oxidative stress on Alzheimer’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

Discovery of specific mutations in spinal muscular atrophy patients by next-generation sequencing

Cough syncope and hyperventilation-induced convulsion in Chiari 1.5 malformation

A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis

Clinical activity changes in the neurology department of Wenzhou during the COVID-19 pandemic: an observational analysis

Economic burden of medication-overuse headache in Iran: direct and indirect costs

Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports